Physician Views snap-poll: Biosimilar versions of Avastin, Herceptin launch in the US

Partners Allergan and Amgen confirmed late last week that the biosimilars Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns), which reference Roche's cancer drugs Avastin (bevacizumab) and Herceptin (trastuzumab), respectively, are now available in the US. More here.

We are snap-polling US-based oncologists with the following questions to ascertain sentiment towards these launches among the physician community…

________

Q. Amgen and Allergan announced late last week that the biosimilars Mvasi (bevacizumab-awwb) and Kanjinti (trastuzumab-anns), which reference the Roche cancer drugs Avastin (bevacizumab) and Herceptin (trastuzumab), respectively, are now available in the US. They are the first available Avastin and Herceptin biosimilar products.

How would you describe your attitude towards this news?

Very negative

Negative

Neutral

Positive

Very positive

________

Q. Kanjinti is approved in all of Herceptin's indications. Mvasi  does not have an identical label to Avastin and is not indicated for the treatment of ovarian cancer.

To what extent do you think lack of a labelled indication for ovarian cancer will act as a barrier to overall adoption of Mvasi?

Not a barrier

Somewhat of a barrier

Moderate barrier

Extreme barrier

________

Q. From a clinical perspective (i.e. excluding any cost consideration), how comfortable would you be prescribing Mvasi as an alternative therapeutic option to Avastin in treatment-naïve patients?

Not comfortable

Slightly comfortable

Somewhat comfortable

Moderately comfortable

Extremely comfortable

________

Q. From a clinical perspective (i.e. excluding any cost consideration), how comfortable would you be prescribing Kanjinti as an alternative therapeutic option to Herceptin in treatment-naïve patients?

Not comfortable

Slightly comfortable

Somewhat comfortable

Moderately comfortable

Extremely comfortable

________

Q. Both biosimilars will have a 15% lower wholesale acquisition cost (WAC) than their reference treatments. Mvasi will be priced at a WAC of $677.40 per 100 mg and $2709.60 per 400 mg single-dose vial, while Kanjinti is being made available at $3697.26 per 420 mg multi-dose vial. At launch, Mvasi will be priced 12% below Avastin's current average selling price, with Kanjinti carrying a 13% lower average selling price versus Herceptin.

Versus your expectations do you think these prices are …?

Very low

Low

About right

High

Very high 

________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.